• Erica N Parker, Samuel O Odutola, Yifan Wang, Tracy E Strecker, Rajeswari Mukherjee, Zhe Shi, David J Chaplin, Mary Lynn Trawick, and Kevin G Pinney.
• Department of Chemistry and Biochemistry, Baylor University, One Bear Place #97348, Waco, TX 76798-7348, United States.
• Bioorg. Med. Chem. Lett. 2017 Mar 1; 27 (5): 1304-1310.

AbstractThe magnitude of expression of cathepsin L, often upregulated in the tumor microenvironment, correlates with the invasive and metastatic nature of certain tumors. Inhibition of cathepsin L represents an emerging strategy for the treatment of metastatic cancer. A potent, small-molecule inhibitor (referred to as KGP94) of cathepsin L, and new KGP94 analogues were synthesized. (3,5-Dibromophenyl)-(3-hydroxyphenyl) ketone thiosemicarbazone (22), with an IC50 value of 202nM, exhibited similar inhibitory activity against cathepsin L compared to KGP94 (IC50=189nM). Due to limited aqueous solubility of KGP94, a water-soluble phosphate salt (KGP420) was prepared in order to facilitate future in vivo studies. Enzymatic hydrolysis with alkaline phosphatase (ALP) demonstrated that the phosphate prodrug, KGP420, was readily converted to the parent compound, KGP94.Copyright © 2016 Elsevier Ltd. All rights reserved.

36 keywords...

hide…